Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gamma delta T-cell infusion
- Development stage
- Phase 1
- Lead developer
- Moffitt Cancer Center
- Modality
- Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an investigational adoptive cellular immunotherapy consisting of ex vivo expanded donor-derived gamma delta (γδ) T cells, specifically the Vγ9Vδ2 subset. Developed by the H. Lee Moffitt Cancer Center and Research Institute, the therapy is designed to prevent relapse in patients with acute myeloid leukemia (AML) following allogeneic hematopoietic stem cell transplantation (alloHCT). The process involves isolating γδ T cells from the transplant donor and expanding them using artificial antigen presenting cells (AAPCs). These cells are then infused into the patient between days 60 and 100 post-transplant. The Vγ9Vδ2 T cells recognize and eliminate residual leukemia cells in an MHC-independent manner, providing a graft-versus-leukemia effect without the typical MHC restrictions of alpha-beta T cells.
- Other names
- Donor γδ T-Cell InfusionAAPC-expanded donor gamma delta T-cellsVγ9Vδ2 T-cell infusion
02
Targets
MICB (Major histocompatibility complex class i-related protein B)PSCA (Prostate stem cell antigen)
Beyond the preview
Go deeper on gamma delta T-cell infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gamma delta T-cell infusion.